Passage Bio, Inc. PASG
We take great care to ensure that the data presented and summarized in this overview for Passage BIO, Inc. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding PASG
View all-
Orbimed Advisors LLC San Diego, CA10.1MShares$11.5 Million0.31% of portfolio
-
Versant Venture Management, LLC San Francisco, CA4.96MShares$5.65 Million9.33% of portfolio
-
Vestal Point Capital, LP New York, NY4.5MShares$5.13 Million0.5% of portfolio
-
New Leaf Venture Partners, L.L.C. New York, NY2.5MShares$2.85 Million2.96% of portfolio
-
Vanguard Group Inc Valley Forge, PA2.07MShares$2.36 Million0.0% of portfolio
-
Tang Capital Management LLC San Diego, CA1.5MShares$1.71 Million0.25% of portfolio
-
Jim Simons Renaissance Technologies LLC | New York, Ny1.21MShares$1.37 Million0.0% of portfolio
-
Acadian Asset Management LLC Boston, MA961KShares$1.1 Million0.0% of portfolio
-
Black Rock Inc. New York, NY923KShares$1.05 Million0.0% of portfolio
-
Israel Englander Millennium Management LLC | New York, Ny866KShares$986,9420.0% of portfolio
Latest Institutional Activity in PASG
Top Purchases
Top Sells
About PASG
Passage Bio, Inc., a genetic medicines company, develops transformative therapies for central nervous system diseases. It develops PBGM01, which utilizes a proprietary, AAVhu68 capsid to deliver to the brain and peripheral tissues a functional GLB1 gene encoding lysosomal acid beta-galactosidase for infantile GM1; PBFT02, which utilizes an AAV1 capsid to deliver to the brain a functional granulin (GRN) and gene encoding progranulin (PGRN) for the treatment of FTD-GRN; and PBKR03, which utilizes a proprietary, AAVhu68 capsid to deliver to the brain and peripheral tissues a functional GALC gene encoding the hydrolytic enzyme galactosylceramidase for infantile Krabbe disease. The company also develops PBML04 for the treatment of metachromatic leukodystrophy; PBAL05 for the treatment of amyotrophic lateral sclerosis; and PBCM06 for the treatment of Charcot-Marie-Tooth Type 2A. Passage Bio, Inc. has a strategic research collaboration with the Trustees of the University of Pennsylvania's Gene Therapy Program; and collaboration agreement, and a development services and clinical supply agreement with Catalent Maryland, Inc. The company was incorporated in 2017 and is headquartered in Philadelphia, Pennsylvania.
Insider Transactions at PASG
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Feb 13
2024
|
Mark S Forman CHIEF MEDICAL OFFICER |
SELL
Open market or private sale
|
Direct |
1,638
-3.26%
|
$0
$0.97 P/Share
|
|
Feb 13
2024
|
Kathleen Borthwick CFO |
SELL
Open market or private sale
|
Direct |
1,470
-4.91%
|
$0
$0.97 P/Share
|
|
Feb 10
2024
|
Mark S Forman CHIEF MEDICAL OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
5,000
+9.05%
|
-
|
|
Feb 10
2024
|
Kathleen Borthwick CFO |
BUY
Exercise of conversion of derivative security
|
Direct |
4,000
+11.79%
|
-
|
|
Jan 02
2024
|
Edgar B. Cale GC & CORPORATE SECRETARY |
SELL
Open market or private sale
|
Direct |
15,813
-25.58%
|
$0
$0.91 P/Share
|
|
Jan 02
2024
|
Kathleen Borthwick CFO |
SELL
Open market or private sale
|
Direct |
10,672
-29.15%
|
$0
$0.91 P/Share
|
|
Jan 02
2024
|
Mark S Forman CHIEF MEDICAL OFFICER |
SELL
Open market or private sale
|
Direct |
15,813
-25.89%
|
$0
$0.91 P/Share
|
|
Dec 31
2023
|
Edgar B. Cale GC & CORPORATE SECRETARY |
BUY
Exercise of conversion of derivative security
|
Direct |
50,000
+44.72%
|
-
|
|
Dec 31
2023
|
Kathleen Borthwick CFO |
BUY
Exercise of conversion of derivative security
|
Direct |
30,000
+45.04%
|
-
|
|
Dec 31
2023
|
Mark S Forman CHIEF MEDICAL OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
50,000
+45.01%
|
-
|
|
Jul 28
2023
|
Simona King Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
11,453
-32.31%
|
$0
$0.88 P/Share
|
|
Jul 28
2023
|
Simona King Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
31,250
+46.85%
|
-
|
|
Jun 28
2023
|
Orbimed Advisors LLC > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
575,195
+6.68%
|
$0
$0.84 P/Share
|
|
Jun 27
2023
|
Orbimed Advisors LLC > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
617,382
+7.64%
|
$0
$0.84 P/Share
|
|
Jun 16
2023
|
Alexandros Fotopoulos Chief Technical Officer |
SELL
Open market or private sale
|
Direct |
4,052
-12.37%
|
$0
$0.93 P/Share
|
|
Jun 15
2023
|
Alexandros Fotopoulos Chief Technical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
12,500
+27.63%
|
-
|
|
Apr 18
2023
|
Simona King Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
2,053
-50.0%
|
$2,053
$1.05 P/Share
|
|
Apr 18
2023
|
Simona King Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
6,250
+50.0%
|
-
|
|
Dec 01
2022
|
Sandip Kapadia |
SELL
Open market or private sale
|
Direct |
5,000
-100.0%
|
$5,000
$1.19 P/Share
|
|
Nov 22
2022
|
Alexandros Fotopoulos Chief Technical Officer |
SELL
Open market or private sale
|
Direct |
3,720
-15.52%
|
$3,720
$1.33 P/Share
|
Last 12 Months Summary
| Open market or private purchase | 1.19M shares |
|---|---|
| Exercise of conversion of derivative security | 183K shares |
| Open market or private sale | 60.9K shares |
|---|